Bluebird Bio Inc. (NASDAQ:BLUE) has been given a $80.00 target price by investment analysts at Jefferies Group in a report released on Thursday. The firm currently has a “buy” rating on the stock. Jefferies Group’s price target indicates a potential upside of 25.10% from the company’s previous close.

Several other research analysts have also issued reports on the stock. Roth Capital started coverage on shares of Bluebird Bio in a report on Thursday, September 22nd. They set a “buy” rating and a $87.00 price target for the company. Goldman Sachs Group Inc. raised shares of Bluebird Bio from a “buy” rating to a “conviction-buy” rating and set a $135.00 price objective for the company in a research report on Thursday, September 15th. Cantor Fitzgerald downgraded shares of Bluebird Bio from a “hold” rating to a “sell” rating and reduced their price objective for the stock from $65.24 to $37.00 in a research report on Friday, October 14th. Leerink Swann raised their price objective on shares of Bluebird Bio from $67.00 to $80.00 and gave the stock an “outperform” rating in a research report on Friday, October 14th. Finally, Maxim Group reaffirmed a “buy” rating and set a $85.00 price objective (down previously from $105.00) on shares of Bluebird Bio in a research report on Thursday, August 4th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and thirteen have issued a buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $82.82.

Analyst Recommendations for Bluebird Bio (NASDAQ:BLUE)

Shares of Bluebird Bio (NASDAQ:BLUE) traded up 2.32% during mid-day trading on Thursday, hitting $63.95. 505,529 shares of the stock were exchanged. Bluebird Bio has a 12-month low of $35.37 and a 12-month high of $95.28. The stock’s 50 day moving average price is $56.23 and its 200-day moving average price is $52.68. The stock’s market capitalization is $2.39 billion.

Bluebird Bio (NASDAQ:BLUE) last released its quarterly earnings results on Wednesday, November 2nd. The company reported ($2.07) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.59) by $0.48. Bluebird Bio had a negative return on equity of 30.79% and a negative net margin of 3,941.72%. The firm had revenue of $1.55 million for the quarter, compared to the consensus estimate of $1.82 million. During the same quarter in the previous year, the business posted ($1.18) EPS. The firm’s revenue for the quarter was up 17.4% compared to the same quarter last year. On average, equities research analysts expect that Bluebird Bio will post ($7.05) EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This article was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this article on another site, it was stolen and reposted in violation of United States and international copyright & trademark legislation. The correct version of this article can be viewed at https://www.thecerbatgem.com/2016/11/24/jefferies-group-reiterates-buy-rating-for-bluebird-bio-inc-blue.html.

In other news, insider Eric Sullivan sold 416 shares of Bluebird Bio stock in a transaction on Monday, October 3rd. The stock was sold at an average price of $67.00, for a total transaction of $27,872.00. Following the sale, the insider now directly owns 5,891 shares in the company, valued at approximately $394,697. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 3.50% of the company’s stock.

Several large investors have recently added to or reduced their stakes in BLUE. Seven Eight Capital LLC acquired a new stake in Bluebird Bio during the first quarter worth approximately $108,000. Quantbot Technologies LP boosted its stake in Bluebird Bio by 431.3% in the second quarter. Quantbot Technologies LP now owns 2,848 shares of the company’s stock worth $123,000 after buying an additional 2,312 shares during the last quarter. First Mercantile Trust Co. acquired a new stake in Bluebird Bio during the third quarter worth approximately $129,000. Sei Investments Co. boosted its stake in Bluebird Bio by 106.7% in the third quarter. Sei Investments Co. now owns 2,515 shares of the company’s stock worth $170,000 after buying an additional 1,298 shares during the last quarter. Finally, Winslow Evans & Crocker Inc. boosted its stake in Bluebird Bio by 170.0% in the third quarter. Winslow Evans & Crocker Inc. now owns 2,700 shares of the company’s stock worth $183,000 after buying an additional 1,700 shares during the last quarter.

About Bluebird Bio

bluebird bio, Inc is a biotechnology company. The Company is focused on developing transformative gene therapies for severe genetic and rare diseases and in the field of T cell-based immunotherapy. Its gene therapy clinical programs include LentiGlobin product candidate to treat transfusion-dependent B-thalassemia (TDT) and severe sickle cell disease (SCD), and Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD), a rare hereditary neurological disorder.

5 Day Chart for NASDAQ:BLUE

Receive News & Stock Ratings for Bluebird Bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bluebird Bio Inc. and related stocks with our FREE daily email newsletter.